8/21/2008

Gardasil, Merck & Co.'s human papillomavirus vaccine designed to prevent cervical cancer, is cost-effective only for preadolescent girls and women as old as 21, according to an economic analysis by Harvard University researchers. The findings support the CDC's recommendation to routinely immunize 11- and 12-year-old girls before they become sexually active.

Related Summaries